FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices

Lawsuit Does Not Cite Overlap In Companies’ Portfolios

The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.

FTC FEDERAL TRADE COMMISSION headquarters building entrance with sign above door and exterior.
The FTC is calling out Amgen for bundled rebate practices • Source: Shutterstock

The US Federal Trade Commission is taking its fight against rebating and bundling practices that pharmaceutical companies employ in negotiations with payers to court, but not by suing to stop these tactics directly. Instead, the FTC said on 16 May that it is filing a lawsuit to block Amgen, Inc.’s $28bn purchase of Horizon Therapeutics plc to prevent the acquirer from obtaining greater power to block competition through drug price rebates it promises to pharmacy benefit managers (PBMs).

KEY TAKEAWAYS
  • The action represents a new tactic for the agency, seeking to block Amgen’s acquisition of Horizon because of the power it will have to affect market access via bundled drug price rebates.

The FTC did not point to any overlap in the two companies’ product portfolios or research and development pipelines, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By 

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.